|
시장보고서
상품코드
2077269
기관지확장증 치료제 시장 : 약물 계열별, 투여 경로별, 유통 채널별, 지역별Bronchiectasis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
기관지확장증 치료제 시장은 2026년에 4억 4,920만 달러 규모에 달할 것으로 추정되며, 2033년에 8억 9,790만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 10.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 4억 4,920만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026-2033년까지 예측 기간의 CAGR: | 10.40% | 2033년 시장 규모 예측: | 8억 9,790만 달러 |
기관지확장증이란, 폐의 관(기도)이 손상으로 인해 확장되거나 주머니 모양으로 변해버리는 질환입니다. 이로 인해 폐에서 점액을 배출하기 어려워져, 감염증을 자주 일으킬 가능성이 있습니다. 고름이나 점액이 동반된 심한 기침이 기관지확장증의 주요 증상입니다. 기관지확장증은 완치될 수는 없지만, 치료를 통해 증상을 관리하는 것은 가능합니다.
기관지확장증 치료제는 기관지의 확장이 특징인 만성 호흡기질환인 기관지확장증의 증상과 합병증을 관리하는 데 필수적입니다. 이러한 약물은 만성 기침, 과도한 가래 생성, 재발성 호흡기 감염 등의 증상을 완화하는 동시에 질병의 진행을 늦추는 것을 목적으로 합니다. 기관지확장증 치료제에는 기관지확장제, 거담제, 항생제, 항염증제 등이 포함됩니다. 이러한 약물의 개발로 인해 환자의 예후와 삶의 질 향상을 위한 새로운 가능성이 열리고 있습니다. 기관지확장증에 대한 지속적인 연구를 통해 새로운 치료 접근법과 표적 치료법이 모색되고 있으며, 이는 보다 효과적인 치료와 질환 관리 개선에 대한 희망을 안겨주고 있습니다.
시장 역학
기관지확장증 유병률의 증가, 치료 옵션의 발전, 맞춤형 의료에 대한 관심 고조가 예측 기간 동안 전 세계 기관지확장증 치료제 시장의 성장을 견인할 것으로 예상됩니다. 또한, 지원적인 규제 환경과 시장 참여자들의 연구 개발 활동 활성화 역시 예측 기간 동안의 시장 성장을 뒷받침할 것으로 전망됩니다.
예를 들어, 2022년 2월, 생명공학 기업인 Armata Pharmaceuticals, Inc.는 미국 식품의약국(FDA)이 자사의 최적화된 주력 치료 후보물질인 AP-PA02에 대해 두 번째 적응증인 비낭포성섬유증성 기관지확장증을 대상으로 한 임상시험을 시작하기 위한 임상시험용 의약품 신청(IND)을 승인했다고 발표했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 기관지확장증 치료제 시장의 주요 기업 개요을 발표하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- '세계 기관지확장증 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 기관지확장증 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 기관지확장증 치료제 시장 : 약물 계열별, 2021-2033년
제5장 기관지확장증 치료제 시장 : 투여 경로별, 2021-2033년
제6장 기관지확장증 치료제 시장 : 유통 채널별, 2021-2033년
제7장 기관지확장증 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.10Bronchiectasis Drugs Market is estimated to be valued at USD 449.2 Mn in 2026 and is expected to reach USD 897.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 449.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.40% | 2033 Value Projection: | USD 897.9 Mn |
Bronchiectasis is a condition where damage causes the tubes in your lungs (airways) to widen or develop pouches. It makes it hard to clear mucus out of your lungs and can cause frequent infections. Coughing a lot with pus and mucus is the main symptom of bronchiectasis. Bronchiectasis can't be cured but can be managed with treatment.
Bronchiectasis drugs are essential for managing the symptoms and complications of bronchiectasis, a chronic respiratory condition characterized by widening of the bronchial tubes. These drugs aim to alleviate symptoms like chronic cough, excessive mucus production, and recurrent respiratory infections while slowing down disease progression. Bronchiectasis drugs encompass bronchodilators, mucus-clearing agents, antibiotics, and anti-inflammatory medicine. Their development has opened new possibilities for improved patient outcomes and quality of life. Ongoing research in bronchiectasis explores novel therapeutic approaches and targeted medications, offering hope for more effective treatments and better disease management.
Market Dynamics:
The increasing prevalence of bronchiectasis, advancements in treatment options, and increasing focus on personalized medicine are anticipated to drive growth of the global bronchiectasis drugs market over the forecast period. Moreover, a supportive regulatory environment and increased research and developmental activities by market players is expected to drive market growth over the forecast period.
For instance, in February 2022, Armata Pharmaceuticals, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bronchiectasis drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, Sunovion Pharmaceuticals, Chiesi Farmaceutici
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bronchiectasis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchiectasis drugs market
Detailed Segmentation:
- Bronchiectasis drugs market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Antibiotics
- Mucolytics
- Bronchodilators
- Anti-inflammatory agents
- Bronchiectasis drugs market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Inhalation
- Intravenous
- Bronchiectasis drugs market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Bayer
- GlaxoSmithKline
- Boehringer Ingelheim
- Novartis
- AstraZeneca
- Sunovion Pharmaceuticals
- Chiesi Farmaceutici
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Bronchiectasis Drugs, By Drug Class
- Market Bronchiectasis Drugs, By Route of Administration
- Market Bronchiectasis Drugs, By Distribution Channel
- Market Bronchiectasis Drugs, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing Prevalence of Bronchiectasis
- Increasing Awareness of the Disease
- Restraints
- Limited Awareness and Underdiagnoses
- Lack of Specific Treatment Guidelines
- Opportunities
- Unmet Medical Needs
- Emerging Markets
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Bronchiectasis Drugs Market , By Drug Class, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Mucolytics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Anti-inflammatory agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
5. Bronchiectasis Drugs Market , By Route of Administration, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
6. Bronchiectasis Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
7. Bronchiectasis Drugs Market , By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- China
- Japan
- India
- South Korea
- ASEAN
- Australia
- Rest of Middle East
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2021 - 2033,(US$ Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Bayer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Chiesi Farmaceutici
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
